Jefferies raises Nvidia stock price target to $205 on strong demand
Steven Sell, the CEO and President of agilon health , inc. (NYSE:AGL), recently reported transactions involving the company’s common stock. The timing is notable as InvestingPro data shows the stock has gained over 12% in the past week, with current trading at $4.32. On March 14, 2025, Sell disposed of 15,563 shares at a price of $4.05 each, resulting in a total transaction value of $63,030. These shares were withheld by agilon health to satisfy tax obligations related to the net settlement of performance-based restricted stock units (PSUs), rather than representing an open market sale.
In addition to this, Sell acquired 42,426 shares of common stock as part of the vesting of PSUs, which were granted on April 14, 2022. The PSUs vested based on the company’s revenue and adjusted EBITDA goals over a three-year period, achieving a total attainment of 87%. Following these transactions, Sell directly owns 355,310 shares, while an additional 67,590 shares are held indirectly through a trust. The transactions come as the company shows strong revenue growth of 40.41% over the last twelve months, though InvestingPro analysis indicates the stock may be overbought at current levels. For deeper insights into insider trading patterns and 10+ additional ProTips, consider accessing the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Agilon Health has reported its fourth-quarter 2024 earnings, showcasing a significant 44% revenue increase year-over-year to $1.52 billion, although the earnings per share (EPS) fell short of expectations at -$0.26 against a forecast of -$0.22. Analysts from Truist Securities have maintained a Hold rating for Agilon Health, adjusting their revenue forecasts for fiscal years 2025 and 2026 to $5.9 billion and $6.2 billion, respectively, indicating a decrease from previous projections. Truist also revised the company’s adjusted EBITDA estimates, predicting a greater loss in 2025 and 2026 than initially expected. Meanwhile, Benchmark analysts have raised their price target for Agilon Health to $4.00, maintaining a Buy rating, and highlighted the company’s strategic moves to exit unprofitable partnerships and renegotiate payer contracts. Stifel analysts also raised their price target to $3.00, emphasizing the company’s shift towards profitability over growth for 2025. Agilon Health’s strategic initiatives include reducing Medicare Part D exposure and enhancing clinical and operational programs, aiming for cash flow breakeven by 2027. These developments reflect Agilon Health’s efforts to manage costs and improve financial performance amidst a challenging market environment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.